Advertisement

Circulating B Lymphocytes in Multiple Myeloma Patients Contain an Autocrine IL-6 Driven Pre-Myeloma Cell Population

  • X. Thomas
  • H. Q. Xiao
  • R. Chang
  • J. Epstein
Part of the Current Topics in Microbiology and Immunology book series (CT MICROBIOLOGY, volume 182)

Abstract

Among the unanswered questions in the development of multiple myeloma are the level of hematopoietic development of the myeloma stem cell,1 the tissue site of initiation (bone marrow? lymph node?) 2,3 and the role of IL-6 in myeloma development. 4-6 The involvement of B lymphocytes in the bone marrow and blood in myeloma has been suggested initially by identifying B cells displaying concordant isotype and idiotype, 7-9 followed by the demonstration of a circulating clonal B cell population with a concordant JH rearrangement.10 Abnormal B cells from the marrow of myeloma patients could be differentiated into the myeloma cells upon stimulation,11 the first functional demonstration of B cell involvement. Similarly, blood mononuclear cells from myeloma patients cultured with IL-3 and IL-612 or co-cultured with autologous bone marrow stromal cells13 differentiated into plasma cells containing the concordant monotypic immunoglobulin.

Keywords

Multiple Myeloma Myeloma Cell Myeloma Patient Human Multiple Myeloma Soft Tissue Site 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Epstein J, Xiao H, He XY(1990) Markers of multiple hematopoietic-cell lineages in multiple myeloma. N Engl J Med 322:664–668.PubMedCrossRefGoogle Scholar
  2. 2.
    Epstein, J (1992) Myeloma phenotype-clues to its origin and manifestation. Hematology/Oncology Clinics of North America 6:249–256.PubMedGoogle Scholar
  3. 3.
    MacLennan ICM, Chan EUT (1991) The origin of bone marrow plasma cells. In: Obrams GI, Potter M (eds) Epidemiology and Biology of Multiple Myeloma. Springer-Verlag, Berlin, pp 129–135.Google Scholar
  4. 4.
    Kawano M, Hirano T, Matsuda T, Taga T, Horii Y, Iwato K, Asaoku H, Tang B, Tanabe O, Tanaka H, Kuramoto A, Kishimoto T (1988) Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature (London) 332:83–85.PubMedCrossRefGoogle Scholar
  5. 5.
    Klein B, Zhang X-G, Jourdan M, Content J, Houssiau F, Aarden L, Piechaczyk M, Bataille R (1989) Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6. Blood 73:517–526.PubMedGoogle Scholar
  6. 6.
    Xiao H-Q, Woodliff J, Epstein J (1992) Autocrine IL-6 production in pre-myeloma cells. Cancer Res. 33: 1372.Google Scholar
  7. 7.
    Mellstedt H, Hammerstrom S, Hohn G (1974) Monoclonal lymphocyte population in human plasma cell myeloma. Clin Exp Immunol 17:371–384.PubMedGoogle Scholar
  8. 8.
    Kubagawa H, Vogler L, Capra JD, Conrad ME, Lawton R, Cooper MD (1979) Studies on the clonal origin of multiple myeloma. Use of individually specific (idiotype) antibodies to trace the oncogenic event to its earliest point of expression in B-cell differentiation. J Exp Med 150:792–807.PubMedCrossRefGoogle Scholar
  9. 9.
    Bast EJEG, van Camp B, Reynaert P, Wiringa G, Ballieux RE (1982) Idiotypic peripheral blood lymphocytes in monoclonal gammopathy. Clin Exp Immunol 47:677–682.PubMedGoogle Scholar
  10. 10.
    Jensen GS, Mant MJ, Belch AJ, Berenson R, Ruether BA, Pilarski LM (1991) Selective expression of CD45 isoforms defines CALLA + monoclonal B-lineage cells in peripheral blood from myeloma patients as late stage B cells. Blood 78:711–719.PubMedGoogle Scholar
  11. 11.
    Caligaris-Cappio F, Bergui L, Tesio L, Pizzolo G, Malavasi F, Chilosi M, Campana D, van Camp B, Janossy G (1985) Identification of malignant plasma cell precursors in the bone marrow of multiple myeloma. J Clin Invest 76:1243–1251.PubMedCrossRefGoogle Scholar
  12. 12.
    Bergui L, Schena M, Gaidano G, Riva M, Caligaris-Cappio F (1989) Interleukin 3 and interleukin 6 synergistically promote the proliferation and differentiation of malignant plasma cell precursors in multiple myeloma. J Exp Med 170:613–618.PubMedCrossRefGoogle Scholar
  13. 13.
    Caligaris-Cappio F, Bergui L, Gregoretti MG, Hiadano G, Goneli M. Schena M, Zallone AZ, Marchisio PC (1991) Role of bone marrow stromal cells in the growth of human multiple myeloma. Blood 77:2688–2693.PubMedGoogle Scholar
  14. 14.
    Pilarski LM, Jensen GS (1992) Monoclonal circulating B cells in multiple myeloma: a continuously differentiating possibly invasive population as defined by expression of CD45 isoforms and adhesion molecules. Hematology/Oncology Clinics of North America 6:297–322.PubMedGoogle Scholar
  15. 15.
    Warburton P, Joshua DE, Gibson J, Brown RD (1989) CD10-(CALLA)-positive lymphocytes in myeloma: evidence that they are a malignant precursor population and are of germinal centre origin. Leukemia Lymphoma 1:11.CrossRefGoogle Scholar
  16. 16.
    Terstappen LWMM, Johnsen S, Segers-Nolten IMJ, Loken MR (1990) Identification and characterization of plasma cells in normal human bone marrow by high-resolution flow cytometry. Blood 76:1739–1747.PubMedGoogle Scholar
  17. 17.
    Petrucci MT, Hata H, Xiao H-Q, Kreitman J, Pastan I, Hsu SM, Epstein J (1991) Significance of inducible IL-6 gene expression by myeloma cells. Blood 78:115a.Google Scholar
  18. 18.
    Caldwell CW and Patterson WP (1991) Relationship between CD45 antigen expression and putative stages of differentiation in B-cell malignancies. American J Hematol 36:111–115.CrossRefGoogle Scholar
  19. 19.
    Jensen GS, Andrews EJ, Mant MJ, Vergidis R, Ledbetter JA, Pilarski LM (1991) Transitions in CD45 isoform expression indicate continuous differentiation of a monoclonal CD5+ CD11b+ B lineage in Waldenstrom’s macroglobulinemia. American J Hematol 37:20–30.CrossRefGoogle Scholar
  20. 20.
    Vescio RA, Cao J, Lichtenstein AL and Berenson JR (1992) IgM-producing B-lymphocytes are part of the malgnant clone in Multiple Myleoma. Cancer Res 33:229.Google Scholar
  21. 21.
    Klein B. Bataille R (1992) Cytokine network in human multiple myeloma. Hematology/Oncology Clinics of North America 6:273–284.PubMedGoogle Scholar
  22. 22.
    Aarden LA. De-Groot ER. Schaap OL. Lansdorp PM (1987) Production of hybridoma growth factor by human monocytes. Eur J Immunol. 17:1411–1416.PubMedCrossRefGoogle Scholar
  23. 23.
    Hansen MB, Nielsen SE, Berg KH (1989) Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill. J Immunol Methods 119:203–210.PubMedCrossRefGoogle Scholar
  24. 24.
    Bataille R, Jourdan M, Zhang XG, Klein B (1989) Serum levels of interleukin-6, a potent myleoma growth factor, as a reflection of disease severity in plasma cell dyscrasias. J Clin Invest 84:2008–2011.PubMedCrossRefGoogle Scholar
  25. 25.
    Justement, LB, Campbell KS, Chien MC, Cambier JC (1991) Regulation of B cell antigen receptor signal transduction and phosphorylation by CD45. Science 252:1839–1842.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1992

Authors and Affiliations

  • X. Thomas
    • 1
  • H. Q. Xiao
    • 1
  • R. Chang
    • 1
  • J. Epstein
    • 1
    • 2
  1. 1.Division of Hematology/Oncology, Department of MedicineArkansas Cancer Research Center, University of Arkansas for Medical SciencesLittle RockUSA
  2. 2.VAMCLittle RockUSA

Personalised recommendations